ERITROGEN 2000 IV INJECTION

Indications

• Anemia due to chronic kidney disease
• Anemia in cancer patients receiving chemotherapy
• Anemia related to HIV infection
• Anemia in patients with myelodysplastic syndromes
• Anemia associated with chronic inflammatory diseases

Dosage

Children: Refer to the BNF for Children for appropriate dosing information based on the indication and patient's age.

Adults: Refer to the specific product information and guidelines for dosing recommendations based on the indication, as doses can vary significantly.

Mechanism of action

Erythropoietin binds to specific receptors on erythroid progenitor cells in the bone marrow, activating intracellular signaling pathways that lead to increased proliferation and differentiation of these cells into mature red blood cells. This process also inhibits apoptosis of erythroid progenitors, thus enhancing red blood cell production.

Pharmacodynamics

The primary pharmacodynamic effect of erythropoietin is the stimulation of erythropoiesis, leading to increased hemoglobin levels and improved oxygen-carrying capacity of the blood. It acts by promoting the survival and proliferation of erythroid progenitor cells, resulting in enhanced production of red blood cells. The onset of action is typically observed within a few days, with peak effects occurring within 1 to 2 weeks after administration.

Pharmacokinetics

Erythropoietin has a relatively short half-life, generally ranging from 4 to 13 hours, depending on the formulation and route of administration. It is primarily eliminated by the kidneys, with a significant portion being excreted in the urine. The drug's bioavailability varies based on the method of administration; subcutaneous administration may have lower bioavailability compared to intravenous routes. The pharmacokinetics can be affected by factors such as renal function, age, and concurrent medications.

Contra-indications

• Uncontrolled hypertension
• Hypersensitivity to erythropoietin or any component of the formulation
• Pure red cell aplasia due to anti-erythropoietin antibodies

Adverse effects

• Hypertension
• Headache
• Fatigue
• Dizziness
• Nausea
• Diarrhea
• Injection site reactions
• Increased risk of thromboembolic events

Interactions

• Increased risk of hypertension with concurrent use of other erythropoiesis-stimulating agents
• Potential interactions with other medications that affect blood pressure

Precautions

• Monitor hemoglobin levels regularly to avoid excessive increases
• Use with caution in patients with a history of cardiovascular disease
• Avoid rapid increases in hemoglobin levels
• Assess for underlying causes of anemia before initiating therapy

Pregnancy

Erythropoietin is classified as Category C. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether erythropoietin is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store vials in the refrigerator at 2°C to 8°C. Do not freeze. Protect from light. Once opened, use within 28 days if stored in a refrigerator.

Formulations

• Injection solution in vials
• Pre-filled syringes